Features

As the industry enters the fourth quarter, how do new drug approvals by FDA’s Center for Drug Evaluation and Research stand now and comparative to recent trends? What is the mix between small molecules and biologics? DCAT Value Chain Insights looks at the products and companies.

With its pending $7.3-billion deal to acquire the bio/pharmaceutical company, Metsera, Pfizer is making a strong play in the obesity drug market. What are the assets that Pfizer will be acquiring, and how do they stack up against the other notable contenders in the obesity drug market?

The US Supreme Court is set to hear oral arguments on November 5, 2025, in a case examining the legal authority of the current Administration to impose tariffs under the International Emergency Economic Powers Act, which was used to impose reciprocal tariffs on a country-by-country basis. What may be next?

How does advanced manufacturing in pharma, such as continuous manufacturing, AI-enabled manufacturing, or distributed manufacturing factor into the current investment activity and policy moves to increase US-based pharma manufacturing? DCAT Value Chain Insights takes an inside look at the latest developments.

In his first major move since taking the helm of Novo Nordisk last month, Mike Doustdar, President and CEO, announced a restructuring plan as the company lowers its sales & profit outlook. What’s behind the move?

Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. DCAT Value Chain Insights rounds up the latest expansions.

With new CEO Maziar Mike Doustdar taking the helm, Novo Nordisk is looking to expand its obesity franchise, with an oral version of it blockbuster weight-loss drug, Wegovy (semaglutide). Will that be the key to changing the fortunes of the company?

What new products, recently or expected to launch in 2025, show blockbuster potential, and do their prospects still remain bright? DCAT Value Chain Insights takes an inside look at the companies & bio/pharmaceuticals rising to the top of the class.

The White House and European Commission have released further details on the recently agreed-to US-EU trade deal, including further details on tariffs on pharmaceuticals. What’s the bottom line for the pharma industry?

The White House released last week a list of major capital investments in the US for manufacturing, including from the pharmaceutical industry. A roundup of investments gaining attention and other moves thus far in 2025.